

Phenotyping for enhanced diagnostics and personalized medicine – A focus on autoimmune diseases& Inflammation

- More than 80 diverse autoimmune diseases affect 6.4% percent of women vs. 2.7 % of men
- Researchers don't know exactly what causes many autoimmune diseases.
- Genetics, diet, infections, and exposure to chemicals might be involved.
- Many subtypes remain excessively difficult to validate and no single test can diagnose most autoimmune diseases.
- Low grade inflammation is central in most pathologies.




Phenotyping for enhanced diagnostics and personalized medicine – A focus on autoimmune diseases& Inflammation

- More than 80 diverse autoimmune diseases affect 6.4% percent of women vs. 2.7 % of men
- Researchers don't know exactly what causes many autoimmune diseases.
- Genetics, diet, infections, and exposure to chemicals might be involved.
- Many subtypes remain excessively difficult to validate and no single test can diagnose most autoimmune diseases.
- Low grade inflammation is central in most pathologies.



Personalized and precision medicine are key a focus in the future





- More than 80 diverse autoimmune diseases affect 6.4% percent of women vs. 2.7 % of men
- Researchers don't know exactly what causes many autoimmune diseases.
- Genetics, diet, infections, and exposure to chemicals might be involved.
- Many subtypes remain excessively difficult to validate and no single test can diagnose most autoimmune diseases.
- Low grade inflammation is central in most pathologies.

Scand J Rheumatol 2019;0:1–10

Personalized Rheumatic Medicine through Dose Reduction Reduces the Cost of Biological Treatment – a retrospective intervention analysis


MK Meyer^{1,2,3,4,5}, M Andersen^{1,2,3}, T Ring^{3,6,7}, GN Andersen^{1,2,4}, LH Ehlers⁷, C Rasmussen^{1,2,5,7}, A Stensballe³*






- Enabling technologies including all
 Omics technologies paves the way to understanding disease etiology.
- Key to insight remains the ability to find good answers to relevant clinical questions
- Why responders and non-responders?


BIOMARKER



- Enabling technologies including all
 Omics technologies paves the way to understanding disease etiology.
- Key to insight remains the ability to find good answers to relevant clinical questions
- Why responders and non-responders?

BIOMARKER







Disease risk (prognosis/Diagnosis/ prevention)



- Enabling technologies including all
 Omics technologies paves the way to understanding disease etiology.
- Key to insight remains the ability to find good answers to relevant clinical questions
- Why responders and non-responders?

BIOMARKER






Disease risk (prognosis/Diagnosis/ prevention)





Patient stratification (Translational biomarkers)



- Enabling technologies including all
 Omics technologies paves the way to understanding disease etiology.
- Key to insight remains the ability to find good answers to relevant clinical questions
- Why responders and non-responders?

BIOMARKER







Disease risk (prognosis/Diagnosis/ prevention)



Patient stratification (Translational biomarkers)



Treatment response (Prediction/monitoring)





Tik Muk Azra



Preterm infants are susceptible to sepsis, which in turn may lead to neurodevelopmental disorders






Tik Muk




NEOMICS

Preterm infants are susceptible to sepsis, which in turn may lead to neurodevelopmental disorders






Preterm infants are susceptible to sepsis, which in turn may lead to neurodevelopmental disorders





Preterm infants are susceptible to sepsis, which in turn may lead to neurodevelopmental disorders











Preterm infants are susceptible to sepsis, which in turn may lead to neurodevelopmental disorders






Tik Muk Azra



NEOMICS


Preterm infants are susceptible to sepsis, which in turn may lead to neurodevelopmental disorders






Preterm infants are susceptible to sepsis, which in turn may lead to neurodevelopmental disorders












Preterm infants are susceptible to sepsis, which in turn may lead to neurodevelopmental disorders












Preterm infants are susceptible to sepsis, which in turn may lead to neurodevelopmental disorders







barrier

Preterm infants are susceptible to sepsis, which in turn may lead to neurodevelopmental disorders









Protected environment



Preterm infants are susceptible to sepsis, which in turn may lead to neurodevelopmental disorders








Protected environment




Preterm infants are susceptible to sepsis, which in turn may lead to neurodevelopmental disorders









Challenged environment:


- Oxygen variability
- Milk mal-digestion
- Bacterial dys-colonization




Preterm infants are susceptible to sepsis, which in turn may lead to neurodevelopmental disorders



Milk and microbiota effects on immunity, gut and brain development is poorly understood



Protected environment




Challenged environment:

- Oxygen variability
- Milk mal-digestion
- Bacterial dys-colonization



Sepsis-induced changes in cerebrospinal fluid affect proteome of the developing hippocampus - correlation to systemic changes



- How systemic infection affects brain development and functions is poorly understood.
- Good biomarkers for early diagnosis and treatment for sepsis-induced brain injury are lacking.

Preterm infant (GA<32 wk)



Control Sepsis Control Sepsis

Formula-fed 5d preterm pigs (90% GA)




Primary hippocampal slices derived from preterm pigs



Collect culture medium and tissue



Sepsis-induced changes in cerebrospinal fluid affect proteome of the developing hippocampus - correlation to systemic changes



- How systemic infection affects brain development and functions is poorly understood.
- Good biomarkers for early diagnosis and treatment for sepsis-induced brain injury are lacking.

Preterm infant (GA<32 wk) Preterm infant (GA\32 wk) Control Sepsis Control Sepsis

Formula-fed 5d preterm pigs (90% GA)








Collect culture medium and tissue




Sepsis-induced changes in cerebrospinal fluid affect proteome of the developing hippocampus - correlation to systemic changes



- How systemic infection affects brain development and functions is poorly understood.
- Good biomarkers for early diagnosis and treatment for sepsis-induced brain injury are lacking.


Preterm infant (GA<32 wk) | Control | Sepsis | Con



AALBORG UNIVERSITY
DENMARK

Collect culture medium and tissue


Sepsis-induced changes in cerebrospinal fluid affect proteome of the developing hippocampus - correlation to systemic



- How systemic infection affects brain development and functions is poorly understood.
- Good biomarkers for early diagnosis and treatment for sepsis-induced brain injury are lacking.



- Dried blood spots offer many advantages as a sample format including ease and safety of transport and handling.
- Dried blood spots are a potentially rich source of protein biomarkers, an area that has been overlooked.






Tik Muk






- Dried blood spots offer many advantages as a sample format including ease and safety of transport and handling.
- Dried blood spots are a potentially rich source of protein biomarkers, an area that has been overlooked.






Tik Muk






Omics analysis of Dried whole blood samples – Whole blood analysis


- Dried blood spots offer many advantages as a sample format including ease and safety of transport and handling.
- Dried blood spots are a potentially rich source of protein biomarkers, an area that has been overlooked.





Tik Muk








Deep proteome coverage reducing missing values for diagnostics and prognostics

Dynamic molecular changes during the first week of human life follow a robust developmental trajectory



Tue B. Bennike







Dynamic molecular changes during the first week of human life follow a robust developmental trajectory



Tue B. Bennike









Dynamic molecular changes during the first week of human life follow a robust developmental trajectory





Tue B. Bennike












Improved phenotyping of disease subtypes by Immunome array

Elevated levels of autoantibodies are present before the clinical diagnosis of auto immune diseases






Proportion of Patients with Positive Antibody Tests Relative to the Time of Diagnosis or Appearance of the First Clinical Manifestation of Systemic Lupus Erythematosus

- Systemic Lupus Erythematosus Up to 28yr
- Rheumatoid Arthritis Up to 16yr
- Multiple sclerosis Up to 14yr

Improved phenotyping of disease subtypes by Immunome array

- Elevated levels of autoantibodies are present before the clinical diagnosis of auto immune diseases
- State-of-the-art personalized protein array technology allows phenotyping of autoantibodies.



Proportion of Patients with Positive Antibody Tests Relative to the Time of Diagnosis or Appearance of the First Clinical Manifestation of Systemic Lupus Erythematosus


- Systemic Lupus Erythematosus Up to 28yr
- Rheumatoid Arthritis Up to 16yr
- Multiple sclerosis Up to 14yr




Improved phenotyping of disease subtypes by Immunome array

- Elevated levels of autoantibodies are present before the clinical diagnosis of auto immune diseases
- State-of-the-art personalized protein array technology allows phenotyping of autoantibodies.

fluid




DENMARK



Proportion of Patients with Positive Antibody Tests Relative to the Time of Diagnosis or Appearance of the First Clinical Manifestation of Systemic Lupus Erythematosus


- Systemic Lupus Erythematosus Up to 28yr
- Rheumatoid Arthritis Up to 16yr
- Multiple sclerosis Up to 14vr





Thomas BG Poulsen Malene M. Jørgensen

- IMMUNOME Discovery Array is a protein array which utilizes the patented Sengenics KREX[™] functional proteomics technology.
- The array contains human proteins from biologically significant protein families including kinases, signalling molecules, cytokines, interleukins, chemokines and cancer antigens.



KREX technology enables autoantibody panels from single to 1600+ individual antigens.









Thomas BG Poulsen Malene M. Jørgensen

- IMMUNOME Discovery Array is a protein array which utilizes the patented Sengenics KREX[™] functional proteomics technology.
- The array contains human proteins from biologically significant protein families including kinases, signalling molecules, cytokines, interleukins, chemokines and cancer antigens.




KREX technology enables autoantibody panels from single to 1600+ individual antigens.











Thomas BG Poulsen Malene M. Jørgensen

- IMMUNOME Discovery Array is a protein array which utilizes the patented Sengenics KREX[™] functional proteomics technology.
- ▶ The array contains human proteins from biologically significant protein families including kinases, signalling molecules, cytokines, interleukins, chemokines and cancer antigens.




KREX technology enables autoantibody panels from single to 1600+ individual antigens.





Low noise of array technology enabling




Glucocorticoid Responsive mechanisms in plasma from Polymyalgia Rheumatica patients



Michael Kruse Meyer


PMR after treatment



Polymyalgia rheumatica is a relatively common inflammatory rheumatic disease.


There are no validated international guidelines available for the diagnosis and treatment of PMR; however, diagnostic and classification criteria are currently being developed.

A quantitative proteome study design to compare with DMARD naïve RA patients and matched controls










- 9 patients included in the study;
- Serum samples before versus after 3 months treatment

Glucocorticoid Responsive mechanisms in plasma from Polymyalgia Rheumatica patients



Michael Kruse Meyer




Polymyalgia rheumatica is a relatively common inflammatory rheumatic disease.

There are no validated international guidelines available for the diagnosis and treatment of PMR; however, diagnostic and classification criteria are currently being developed.

A quantitative proteome study design to compare with DMARD naïve RA patients and matched controls

DENMARK






Glucocorticoid Responsive mechanisms in plasma from Polymyalgia Rheumatica patients




Michael Kruse Meyer





Polymyalgia rheumatica is a relatively common inflammatory rheumatic disease.


There are no validated international guidelines available for the diagnosis and treatment of PMR; however, diagnostic and classification criteria are currently being developed.

A quantitative proteome study design to compare with DMARD naïve RA patients and matched controls






















- Malene Møller Jørgensen
- Rikke Bæk
- Rikke Gry Nielsen (vet)
- Jonathan Blackburn Sengenics







Dres Damgaard

- Svend Birkelund
- Tue Bjerg Bennike

University, Denmark

- Thomas B. G. Poulsen
- Joakim Bastrup
- Ditte Kristensen
- Kenneth Kastanjegaard
- Michael Kruse Meyer



Translational Biomarker Research Unit, Aalborg

























- Tik Muk
- Ping ping Jiang
- Ninh Duc Nguyen

